TABLE 6.
Post hoc subgroup analysisa
| CZA monotherapy group (n = 41) | CZA combination therapy group (n = 64) | MVB monotherapy group (n = 22) | P value | |
|---|---|---|---|---|
| No. of clinical successes (%) | 26 (63.4) | 39 (60.9) | 15 (68.2) | 0.83 |
| No. of 90-day mortalities (%) | 9 (22.0) | 20 (31.2) | 6 (27.3) | 0.58 |
| No. of recurrences of CRE infection (%) | 9 (22.0) | 6 (9.4) | 3 (13.6) | 0.20 |
| No. of increases in study drug MIC in mg/liter (%) | 5 (12.2) | 1 (1.6) | 0 | 0.03 |
| No. of emergences of study drug resistance (%) | 3 (7.3) | 0 | 0 | 0.07 |
| No. of all adverse events (%) | 14 (34.2) | 22 (34.4) | 5 (22.7) | 0.57 |
| No. with nephrotoxicity (%) | 10 (24.4) | 16 (25.0)b | 2 (9.1) | 0.27 |
| No. of initiations of RRT (%) | 1 (2.4) | 2 (3.1) | 0 | 1.0 |
| Median time to start RRT from study drug initiation (days) (IQR) | 13.6 | 7.2 (4.7–9.7) | 0 | |
| No. with leukopenia (%) | 4 (9.8) | 7 (10.9) | 2 (9.1) | 1.0 |
| No. with rash (%) | 3 (7.3) | 1 (1.6) | 1 (4.6) | 0.31 |
| No. with neurotoxicity (%) | 0 | 1 (1.6) | 0 | 1.0 |
a
CRE, carbapenem-resistant Enterobacteriaceae; ICU, intensive care unit; IQR, interquartile range; RRT, renal replacement therapy.
b
Combination therapy use with CZA: colistin (37.5%), polymyxin B (25%), tigecycline (25%), fluoroquinolone (18.8%), aminoglycoside (6.3%).